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1. INTRODUCTION 
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Plants as well as other natural sources have been used since ancient times as a means of 
medicinal therapy. Previously the root of a plants healing power was not known, however 
due to advances in technology and laboratory techniques, it can now be traced at least in 
part, to the various plant metabolites and active substances occurring uniquely within 
each herbal component. Among the main active constituents isolated are alkaloids, which 
consist of a large and diverse group of nearly 10,000 important secondary metabolites 
found abundantly in practically all plants, as well as in various species of animals, 
microorganisms, marine life and insects.  
 Alkaloids can be divided into various categories, depending on their chemical 
structures. An important family of alkaloids is isoquinoline alkaloids, which can further 
be divided into several sub-classes including benzylisoquinolines, phthalideisoquinolines, 
protopines, morphine, ipecac, and protoberberine type. Isoquinoline alkaloids are derived 
from amino acids tyrosine and phenylalanine and plants containing these alkaloids posses 
a wide array of pharmacological activities, many of which affect the nervous system. 
Notably plants from family‟s Papaveraceae, Amaryllidaceae, Ranunculaceae, and 
Fumariaceae are rich in these constituents.  
 Recently, attention has been drawn to isoquinoline alkaloids due to their potential 
as being potent inhibitors of acetylcholinesterase (AChE). For this reason, studies aimed 
at new or alternative therapies for neurodegenerative diseases connected to cholinergic 
depletion, such as Alzheimer‟s disease (AD), have shown increasing interest in further 
investigation of these compounds.  
AD is a progressive form of dementia characterized by widespread loss of central 
cholinergic function affecting mainly the elderly population. In 2005, it was estimated 
that 24 million people suffer from dementia and that this amount will double every 20 
years to 42 million by 2020 and 81 million by 2040. Within the spectrum of dementias, 
Alzheimer‟s dementia is the most prevalent subtype, accounting for about 60% of all 
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dementias [1]. Since there still remains no cure to prevent or treat AD, current therapy is 
based on the symptomatic treatment by use of AChE inhibitors.  
 One genus known to contain several species with AChE inhibitory activity is the 
genus Corydalis.  Classified within this genus is Corydalis yanhusuo, a plant that has 
been used in traditional Chinese medicine for hundreds of years owing to its vast array of 
therapeutic indications. The tuber of C. yanhusuo is known to encompass various 
biologically active constituents, including isoquinoline alkaloids. Thus, it will be the 
topic of this diploma thesis to further investigate the extracts isolated from the tubers of 
C. yanhusuo and evaluate their inhibitory activity on AChE for potential use as natural 
alternatives in AD therapy.  
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2. AIM OF WORK 
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1) Isolation of one alkaloid in pure form from chromatographic fraction. The fraction 
was prepared from primary extract of tubers from Corydalis yanhusuo. Methods of 
isolation were carried out on column chromatography and thin-layer chromatography. 
 
2) Determination of physico-chemical properties of isolated compounds (optical rotation 
and Rf values in two chromatographic systems – TLC). Determination of MS and 
NMR spectra.  
 
3) Determination of antioxidant activity (DPPH test) and influence on human 
cholinesterases – acetylcholinesterase and butyrylcholinesterase. 
 
4) Calculation of IC50, EC50 (statistical program GraphPad from faculty web pages). 
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3.1 Corydalis yanhusuo 
Kingdom: Plantae  
Phyllum: Tracheophyta  
Class: Magnoliopsida  
Order: Papaverales 
Family: Fumariaceae 
Genus: Corydalis 
Botanical name: Corydalis yanhusuo W.T.Wang 
 
 
Fig. 1 Corydalis yanhusuo [2] 
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3.1.1  History and origin  
The genus Corydalis (Fumariaceae) of roughly 320 species is widely distributed in the 
northern hemisphere and about 70 species are known to be used in traditional herbal 
remedies [3]. Corydalis yanhusuo W.T.Wang, a perennial herb belonging to the 
Fumariaceae family and important species of genus Corydalis, has been used in 
traditional herbal remedies in China, Japan, and Korea. C. yanhusuo grows wild in 
Siberia and Northern China and is cultivated principally in the Zhejiang province, where 
it is collected in the early summer season after the stems and leaves have wilted. The 
dried and pulverized tuber is also referred to as Rhizoma Corydalis. It is officially listed 
in the Chinese Pharmacopoeia, and in traditional Chinese medicine it has been used for 
hundreds of years in the treatment of gastric and duodenal ulcers, cardiac arrhythmia, 
rheumatism and dysmenorrhea [4]. C. yanhusuo has also been used to promote blood 
circulation, reinforce vital energy, move qi, and alleviate pain such as headache, chest 
pain, hypochondriac pain, epigastric pain, abdominal pain, backache, arthralgia, or 
trauma [5, 6].  
 
3.1.2. Morphological description 
 The herbs of C. yanhusuo are perennial.  The tuber is yellow, rounded, and about 1-2.5 
cm in diameter. Stems are erect, 10-30 cm, with one or sometimes two scale leaves. 
Leaves are biternate or nearly triternate with leaflets measuring approximately 2-2.5 cm × 
5-8 mm. Flowers are usually between 5-15 and bloom between April and June. Bracts are 
lanceolate or narrowly ovate, measuring 5-12 × 2-5 mm and sometimes lower bracts are 
slightly divided. The pedicel measures about 10 mm at flowering and in fruit up to 
20mm. Outer petals are broad with dentate limbs and the spur of the upper petal is up 
curved, cylindrical, and measures about 11-13 mm. Lower petals have a short claw and 
inner petals measure 8-9 mm with claw longer than petal lobes. The stigma is nearly 
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orbicular while papillae are longer than in preceding species. Capsule are linear and 
measure between 20-28 mm and seeds are found in one row [7]. 
 
3.1.3. Chemical Constituents 
The tuber of C. yanhusuo contains several tertiary and quaternary alkaloids that form the 
main bioactive components. However, there are still many alkaloids in the tubers that 
remain un-investigated, especially those in the micro, or even trace concentrations, which 
cannot be easily separated and identified by traditional phytochemical methods [8]. 
Among those identified, nearly 20 alkaloids of the tertiary and quaternary types have 
been isolated from C. yanhusuo thus far, which may be responsible for the biological 
activities of the drug. Their chemical structures belong to the isoquinoline family of 
alkaloids and can be divided into various skeletal structures [9]. They include protopine 
type: protopine and allocryptopine, and protoberberine/aporphine type: 
tetrahydropalmatine, palmatine, corydaline, dehydrocorydaline, berberine, 
pseudoberberine, canadine, columbamine, tetrahydrocolumbamine, glaucine, 
dehydroglaucine, corybulbine, dehydrocorybulbine, tetrahydrocoptisine, pseudocoptisine, 
and fumaricine [10]. 
 
3.1.4.  Pharmacological Activity of Main Alkaloid Constituents 
Numerous alkaloids displaying a wide range of pharmacological actions including 
analgesic [11, 12], anxiolytic [5], hypnotic [8], antiamnestic [9, 13] anti-inflammatory 
[14-16], antiplatelet [17] and cardioprotective [3, 18, 19] have been isolated form the 
tuber of Corydalis.  
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3.1.4.1 Tetrahydropalmatine 
One of the main active constituents isolated from C. yanhusuo is dl- tetrahydropalmatine 
(dl-THP). Derived from the tetrahydroprotoberberine backbone structure, dl-THP belongs 
to the isoquinoline alkaloid family [5]. It can also be directly synthesized from 
laudanosine, a benzylisoquinoline alkaloid via chemical conversion [20]. 
 Pharmacologically, it has been shown that dl-THP exerts marked analgesic, 
sedative-tranquilizing and hypnotic action and it has been listed in the Chinese 
Pharmacopoeia since 1977 for these indications [8, 11]. It was found that dl-THP could 
display such effect, probably due to its antagonistic action on the D1/D2 receptor in the 
brain [21]. However, in a study by Leung et al., 2003, it was proposed that dl-THP could 
also act on the benzodiazepine site (BDS) of the GABAA receptor in the mouse brain. 
The main findings from the animal behavioral tests concluded that dl-THP manifests 
anxiolysis at defined low dosages at least in part, and this effect is mediated through the 
BDS, thus concluding that the anxiolytic effects of dl-THP could be produced by a 
combination of effects from several receptors in the CNS including D1/D2 receptor and 
GABAA receptor [5]. 
 Studies aiming to distinguish between the various mechanisms of action by which 
dl-THP functions in the CNS have been carried out and in one such study, it was shown 
that dl-THP depletes levels of the neurotransmitters dopamine, noradrenaline and 
serotonin in the central nervous system [22].  In addition, it has been reported that the two 
enantiomers of dl-THP act on different targets – d-THP depletes dopamine while l-THP 
functions as a dopamine antagonist [23]. Interestingly, it was also found that dl-THP 
decreases both arterial pressure and heart rate through a serotonergic release process in 
the hypothalamus [24].  
 In a recent study by Oh et al., 2010, on the inhibition of pro-inflammatory 
mediators, THP inhibited lipopolysaccharide (LPS)-induced interleukin (IL)-8 production 
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in a dose-dependent manner. Furthermore, THP inhibited extracellular signal-regulated 
kinase and p38 mitogen-activated protein kinase (MAPK) phosphorylation, which 
suggests that THP inhibits IL-8 secretion by blocking MAPK phosphorylation [14]. 
 
 
Fig. 2 Tetrahydropalmatine 
 
3.1.4.2  Dehydrocorydaline 
In a study by Kubo et al., 1993, on the potential anti-inflammatory activities of 
methanolic extract from Corydalis tuber, it was found that among the tested alkaloidal 
components, dehydrocorydaline showed a stronger inhibitory effect than that of the 
standard drug, in this case disodium cromoglycate [15]. The methanolic extract of 
Corydalis tuber showed an inhibitory effect against histamine release from mast cells but 
also inhibitory effect on the released histamine when administered to isolated guinea pig 
ileum. It was therefore suggested as having a potentially important future implication in 
the therapeutic field of inflammatory disease [15].  
 Studies also show that dehydrocorydaline not only inhibits antibody-mediated 
allergic reactions but also influences cell-mediated allergic reactions [25]. 
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Fig. 3 Dehydrocorydaline 
 
3.1.4.3   Protopine 
Protopine was reported to exhibit an inhibitory activity on platelet aggregation [17]. 
Protopine was also found to possess potent anti-nociceptive effects due to its ability to 
function as an inhibitor of both serotonin and noradrenaline transporters [12]. It has also 
been described that following treatment with protopine, a significant decrease in 
glutamate level and an increase in glutamate dehydrogenase activity was observed in rat 
brains [26]. Since glutamate plays a significant role in nociceptive processing in central 
and peripheral nervous systems [27, 28], the decrease in glutamate level might also be 
associated with the anti-nociceptive effects of protopine [10].  
 
 
 
Fig. 4 Protopine 
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3.1.4.4   Pseudocoptisine  
Based on a study conducted by Hung et al., 2008, it was found that psuedocoptisine 
displayed remarkable cognitive-enhancing activity mediated in part by its ability to 
inhibit adult male rat AChE activity in a dose dependent manner (IC50 = 12.8 μM) [13]. 
Pseudocoptisine treatment (2.0, 5.0 mg/kg) also reversed the deficits produced by 
scopolamine treatment in the comparison with the vehicle-treated group on passive 
avoidance task. At a concentration of 2.0 mg/kg, pseudocoptisine significantly shortened 
the escape latency and improved swimming time within the zone of platform on water 
maze task [13]. The passive avoidance test is generally accepted as an indicator of long-
term memory in animals [29], and the water maze-learning task was used to asses 
hippocampal-dependent spatial learning ability [30, 31].  
 Pseudocoptisine caused dose-dependent reductions in the levels of inducible nitric-
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at both protein and mRNA levels 
and concomitant decrease in PGE2 and NO production. In addition, it was found that 
pseudocoptisine suppressed the production and mRNA expressions of pro-inflammatory 
cytokines, such as, TNF-α and IL-6 [16].   
 
 
Fig. 5 Pseudocoptisine 
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3.1.4.5  Pseudoberberine  
In a recent in vivo experiment, Hung et al., 2008, found that pseudoberberine inhibited 
mouse brain cortex AChE activity in a dose-dependent manner with an IC50 value of 4.5 
μM. Also, treatment in mice with 5.0mg/kg could reverse the deficits produced by 
scopolamine in comparison with vehicle-treated group on passive avoidance task, and 
significantly shortened the escape latency and improved the swimming time within the 
zone of platform on water maze task when evaluating spatial learning [9].  
 
 
Fig. 6 Pseudoberberine 
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3.2  Other Corydalis species 
 
In addition to the officially listed C. yanhusuo, there are many species of the genus 
Corydalis known to be of use in traditional Chinese medicine or folk medicine.  
 
3.2.1  Corydalis speciosa 
Corydalis speciosa has been used in Korea and China as a folk medicine for its 
antipyretic, analgesic and diuretic properties. In a study by Kim et al., 2004, the 
methanolic extracts of the aerial parts of C. speciosa were found to exhibit significant 
AChE inhibitory activity. Four compounds were separated as active constituents and 
identified as corynoxidine, protopine, palmatine and berberine [32]. All four compounds 
inhibited male mouse AChE in a dose-dependent manner with IC50 values of 89.0, 16.1, 
5.8, and 3.3 μM respectively [32].  
 
                 
                        
                Fig. 7 Corynoxidine              Fig. 8 Protopine 
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               Fig. 9 Palmitine                                 Fig. 10 Berberine  
 
3.2.2  Corydalis cava 
In a study using plants from Danish folk medicine described as memory enhancers, a 
crude methanolic extract of tubers from Corydalis cava demonstrated that corydaline, a 
tetrahydroberberine skeletal type alkaloid, inhibited AChE in a dose-dependent manner. 
The heads of Drosophila melanogaster were used as the enzyme source and an IC50 value 
of 15μM± 3μM was obtained along with bulbocapnine with an IC50 value of 40 ± 2 μM 
from [33]. 
 
Fig. 11 Bulbocapine 
 
3.2.3  Corydalis saxicola 
Corydalis saxicola is a perennial herb native to China, and in traditional Chinese 
medicine it has been noted for its use in the treatment of inflammation, pain, and hepatic 
diseases. In a recent study by Cheng et al., 2008, it was determined through a DNA 
cleavage assay that the alkaloids specifically inhibited topoisomerase through 
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stabilization of the enzyme–DNA complex. Among the isolated alkaloids, pallidine and 
scoulerine showed strong inhibitory activities toward topoisomerase I that were 
comparable to camptothecin, an atypical topoisomerase I inhibitor [34]. Interestingly, in 
another study on C. saxicola, it was found that alkaloidal constituents within this plant 
exhibited potential anti-hepatitis B activity [35].   
 
 
   
 
Fig. 13  Pallidine    Fig. 14  Scoulerine 
 
Another of the main active constituents of C. saxicola, dehydrocavidine, was 
found to exhibit a potent hepatoprotective effect on CCl4-induced liver injury in rats 
owing to its antioxidant activity. In a recent study by Wang et al., 2008, both pre- and 
post-treatment with dehydrocavidine prior to CCl4 administration significantly prevented 
increases in serum enzymatic activities of alanine aminotransferase, aspartate 
aminotransferase, lactate dehydrogenase, alkaline phosphatase and total bilirubin. Thus it 
was concluded that dehydrocavidine displays a potent hepatoprotective effect on CCl4-
induced liver injury in rats mediated through its antioxidant activity [36].  
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Fig. 12 Dehydrocavidin 
 
 
3.3.  Alzheimer’s disease 
Although age-related loss of memory and cognitive decline have been documented for 
thousands of years in human history, AD has only existed as a defined medical condition 
for roughly 100 years. As with many other conditions, ancient writings suggest remedies 
based on natural compounds and plant extracts. An example of such historical indications 
is Withania somnifera, or Ashwagandha in ancient Sanskrit, which was renowned in 
Ayurvedic medicine as „medharasayan‟ or promoter of learning and memory retrieval in 
ancient India almost 4,000 years ago [37].   
 AD is a progressive and fatal neurodegenerative disorder manifested by cognitive 
and memory deterioration, progressive impairment of activities of daily living, and a 
variety of neuropsychiatric symptoms and behavioral disturbances [38]. In AD, the 
progressive nature of neurodegeneration suggests an age-dependent process that 
ultimately leads to degeneration of the synaptic afferent system, dendritic and neuronal 
damage, and formation of abnormal protein aggregates throughout the brain [39]. The 
main neuropathological changes associated with AD are β-amyloid (βA) plaques, 
neurofibrillary tangles (NFT‟s), and neuronal loss or dysfunction. The NFTs accumulate 
as abnormal components of the neuronal cytoskeleton aggregated into paired helical 
 25 
 
filaments, whereas the plaques are comprised of dystrophic neurites and glial elements 
and have a core of amyloid peptide, which is derived from a larger amyloid precursor 
protein (APP).  
Although the senile plaques and NFTs are considered to be the pathological 
hallmarks, there is strong evidence that multiple neurotransmitter systems are affected in 
the AD brain. Since the most prominent abnormalities are seen to arise in the cholinergic 
system, the cholinergic hypothesis of AD was suggested, and further became the leading 
strategy for the development of AD medication.   
 
3.3.1  Pathological hallmarks of Alzheimer’s disease 
 
3.3.1.1 β-Amyloid plaques 
The amyloid cascade is a sequence of events typically seen in AD which leads to the 
abnormal processing of the APP causing production, aggregation, deposition and toxicity 
of its Aβ derivative [40]. The production of Aβ from APP is dependent upon the 
activities of two enzymes, β-secretases and γ-secretases. The APP molecule is cleaved at 
different positions by two individual proteases, α- and β-secretase, further leading to the 
release of the large soluble N-terminal fragments, α-APPs and β-APPs, respectively. 
Cleavage by α-secretase occurs within the region containing Aβ, consequently preventing 
the formation of Aβ. However, since β-secretase cleavage generates the free N-terminus 
of Aβ, it is considered the first critical step in amyloid formation [41].  
 
3.3.1.2 Presenilins and tau-phosphorylation 
Presenilins are two proteins, presenilin 1 (PS1) and presenilin 2 (PS2), located in 
intracellular membranes, which are primarily expressed in neurons and universally 
expressed in the brain [42]. PS1 is required for proper formation of the axial skeleton and 
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is involved in normal neurogenesis and survival of progenitor cells and neurons on 
specific brain regions. PS1 also takes part in γ-secretase activity and binding of PS 
proteins to APP may play an important role in inducing intercellular signaling. Two 
conserved transmembrane aspartate residues in PS1 are critical for Aβ production, 
suggesting that PS1 either functions as an essential cofactor for γ-secretase, or is itself γ-
secretase [43]. 
Mutations in genes of APP and presenilins have been shown to modify the 
processing of APP, through alteration of secretase activities. This process leads to an 
increase in Aβ and may trigger aggregation and induce the path to neurodegeneration 
[44]. The majority of early onset familial AD cases are caused by mutations within the PS 
genes [45]. 
 Tau is a phosphoprotein containing multiple phosphorylation sites belonging to 
the family of microtubule associated proteins and widely expressed in the brain [45]. The 
primary function of tau is to maintain microtubule stability [46]. It is also found as the 
major component of NFTs. According to the tau and tangle theory, in AD the natural role 
of tau in stabilizing microtubules is impaired. Aggregated tau becomes 
hyperphosphorylated, where by reducing its ability to bind microtubules, and 
consequently diseased neurons microtubules are gradually replaced by tangles [45, 47].  
 
3.3.2  The Cholinergic hypothesis  
The cholinergic hypothesis of AD evolved from original observations by Davies and 
Maloney in 1976, which first reported decreased numbers of cholinergic neurons in 
autopsy brain tissue from patients with AD [48, 49]. The cholinergic hypothesis was 
supported by observations in loss of cholinergic markers, such as choline 
acetyltransferase and AChE, in patients with AD at post-mortem [50, 51], along with the 
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correlation of mental test scores and severity of dementia with cholinergic abnormalities 
in late-stage AD [48, 52]. 
 Acetylcholine (ACh) is produced in cholinergic neurons from acetyl coenzyme A 
(CoA) and choline by the action of the enzyme choline acetyltransferase. ACh is 
concentrated in vesicles by the action of the vesicular ACh transporter and released from 
presynaptic cells following depolarization. The activation of postsynaptic muscarinic 
ACh and nicotinic receptors leads to the activation of biochemical pathways or 
depolarization of the target cell and thus, the propagation of the nerve impulse.  
In the synaptic cleft, ACh is quickly inactivated by ChEs, breaking it down to 
acetate and choline. Two ChEs are present in mammals: AChE, which selectively 
hydrolyses ACh, and BuChE, which is capable of hydrolyzing ACh as well as other 
choline esters [53].  
Both AChE and BuChE exist in several globular and asymmetrical forms. A G4 
tetrameric form comprised of four globular protein subunits, and a G1 monomeric form 
with a single globular protein moiety are known to coexist [54].  The proportions of G1 
and G4 forms vary in different human brain regions [55], but for both enzymes, G4 is 
found as the predominant isoform in the mature healthy brain [56].  
At the molecular level, the structure of BuChE is similar to that of AChE, 
displaying only a slight difference in its amino acid sequence [57]. Both enzymes have a 
primarily hydrophobic active gorge, shown by X-ray crystallography to be 20 Å deep for 
AChE, into which ACh diffuses and is cleaved [58]. Once ACh enters this active site, it 
binds at two locations, a catalytic region near the base of the gorge and a choline-binding 
site midway up. Structural features of the two ChE enzymes explain the differences in 
their substrate specificity.  
It has been proposed that the efficiency with which AChE and BuChE hydrolyze 
ACh is dependent on the substrate concentration. AChE shows greater catalytic activity 
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at low ACh concentrations, resulting in substrate inhibition at higher doses, whereas 
BuChE is more efficient at high substrate concentration [59]. These differences in the 
enzymatic kinetic properties and locations of brain AChE and BuChE propose that in the 
normal brain, AChE is the main enzyme responsible for ACh hydrolysis while BuChE 
maintains a supportive function [60]. However, it is interesting to note that in patients 
with AD, BuChE levels in the brain and CSF are found to increase whereas those of 
AChE decrease [61].  
BuChE is widely distributed in the brain regions affected in AD, such as the 
temporal cortex, hippocampus and amygdala. Nuclei expressing high proportions of 
BuChE are implicated in working memory, attention, executive function and behavior, all 
of which are universal deficits in AD [62]. What is more, ACh metabolism may become 
increasingly dependent on BuChE activity as AD progresses [63, 64] and thus the 
inhibition of BuChE in addition to AChE would be expected as a valuable therapeutic 
approach [65].  
It is proposed that both AChE and BuChE may also have a role in the aggregation 
of Aβ that occurs in the early stages of senile plaque formation [66]. As AD progresses, 
there is evidence indicating that both G1 forms AChE and BuChE become increasingly 
accumulated within the amyloid plaques and NFT‟s [66, 67]. Since levels of the G1 form 
of both enzymes are found to be positively correlated with plaque density and 
pathogenicity, inhibiting these enzymes could potentially augment cholinergic function in 
AD [68]. Thus, classical cholinergic signal transduction pathways may protect against 
neuronal degeneration by various routes including modifications in the formation of 
amyloidogenic compounds and reductions in tau-phosphorylation [69], as well as 
reductions in neuronal vulnerability to Aβ toxicity [70]. 
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3.3.3  Current therapy in Alzheimer’s disease 
Currently, cholinesterase inhibitors are classified pharmacologically into three groups on 
the basis of their duration of inhibition- short acting, intermediate acting, and long acting. 
Donepezil and galanthamine are relatively selective for AChE and are fully reversible 
inhibitors that bind briefly to AChE and then dissociate to restore enzyme activity. 
Tacrine and rivastigmine co-inhibit both AChE and BuChE. Rivastigmine is a very 
slowly reversible („pseudo-irreversible‟) inhibitor of both AChE and BuChE and tacrine 
produces reversible inhibition [65]. The pattern and types of symptomatic benefits differ 
between ChE´s and suggestions have attributed these differences in pharmacological 
effect to the various ChE forms within the CNS [71, 72]. 
In 1993, tacrine (Cognex®), an aminoacridine, was the first FDA approved AChE 
inhibitor for the treatment of cognitive decline in patients with AD. Since then, several 
other AChE inhibitors have appeared on the market including the piperidine derivative 
donepezil (Aricept®) in 1996, rivastigmine (Exelon®) in 2000, and the naturally based 
galanthamine (Reminyl®) in 2001 [73]. 
 Recently in 2004, memantine (Namenda, Axura®), an N-methyl-D-aspartate 
(NMDA) receptor antagonist was approved by the FDA on the basis of glutamate-
mediated neurotoxicity in AD [74]. Memantine functions as a neuroprotective at least in 
part through the inhibition of excitoxicity, which if not halted, leads to neuronal injury or 
death through over-stimulation of the NMDA receptors by excess exposure to the 
neurotransmitter glutamate [75]. 
 Controlled clinical trials still prove the use of ChE inhibitors as being the most 
consistently successful method for treating the cognitive, functional and behavioral 
symptoms associated with AD [53]. In comparison to untreated AD patients, whose 
cognitive functions were reported to decline, those treated with ChE inhibitors were 
reported to display cognitive improvements from baseline [76, 77]. ChE inhibitor 
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treatment has also been proven to enhance quantitative electroencephalogram coherence 
with decreased slow-wave activity and increased faster frequencies, reflecting increased 
cortical arousal, improvements in concentration, sensory processing, learning, and 
memory [78, 79]. A recent meta-analysis by Trinh et al., 2003, involving six randomized, 
double-blind, placebo-control trials of ChE inhibitors, concluded that as a class, these 
agents display a modest, beneficial impact on neuropsychiatric symptoms in patients with 
mild-to-moderate probable AD [80]. Although further investigations into evaluating the 
effectiveness of AChE and/or BuChE inhibitors are still needed, they currently remain 
and hold a promising future as the drugs of choice in treating the symptoms associated 
with mild-to-moderately severe forms of AD. 
 
 
3.4 Natural compounds influencing the metabolism of AChE and 
BuChE 
From 1981 to 2006, 63% of all low molecular weight drugs developed where from 
natural products or natural product-derived compounds [81]. In the quest for additional 
AChE inhibitors, various medicinal plants and natural resources have been screened in 
the hope of finding substances with comparative IC50 values to those of currently 
approved drugs on the market. The search for plant derived inhibitors of AChE has 
accelerated inlight of the benefits of these drugs not only in the treatment of AD but in 
other forms of dementia [82]. There are currently only a few synthetic medicines for the 
treatment of cognitive dysfunction and memory loss associated with mild-to-moderate 
AD [83]. Many of these compounds have been reported to present adverse effects 
including GIT disturbances, hepatotoxicity and problems associated with bioavailability 
[84-86], which further promotes the interest in finding more effective AChE inhibitors 
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from natural resources. Supplementary details beyond this text of natural product 
inhibitors of AChE can be found in reviews by Hostettmann et al., 2006, [87] and 
Mukherjee et al., 2007, [83].  
 
3.4.1  Alkaloids 
 
3.4.1.1 Physostigmine, Physostigma venenosum, Fabaceae 
Physostigma venenosum was traditionally used in Africa as a ritual poison. Treatment 
with the indole alkaloid physostigmine, a short-acting reversible AChE inhibitor, isolated 
from P. venenosum, has shown cognitive benefits in both normal and AD patients [83]. 
However, due to its short half-life, physostigmine was found clinically impractical since a 
multiple dosing scheme would be required. Instead, the chemical structure of 
physostigmine was used as a prototype for the development of rivastigmine, a carbamate 
based AChE inhibitor now approved under the trade name Exelon® for symptomatic 
treatment of mild-to-moderately severe AD. 
 
3.4.1.2    Galanthamine, Galanthus nivalis, Amaryllidaceae 
Galanthus nivalis was used traditionally in Bulgaria and Turkey for neurological 
conditions. Initially derived from the extracts of snowdrop and daffodil bulbs, 
galanthamine is now a synthetically produced AChE inhibitor. In a randomized, 6-month, 
multicenter clinical trial, galanthamine showed improvements in activities of daily living 
and behavioral symptom when compared to placebo in patients with probable AD or 
vascular dementia [82]. Galanthamine can be taken as a novel representative for 
successful natural product substitution in place of synthetic drug treatment in AD. 
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3.4.1.3    Huperzine A, Huperzia serrata, Lycopodiaceae 
Huperzia serrata is a moss used to treat contusions, strains, hematuria and swelling in 
traditional Chinese medicine [88]. The sesquiterpene alkaloid huperzine A is a potent, yet 
reversible inhibitor of AChE. In a study by Raves et al., 1997, huperzine A improved 
memory retention process in cognitively impaired aged and adult rats [89]. In China, 
studies conducted by Wang et al., 2006, showed enhancement in memory, cognitive 
skills, and improvements in daily activities, after administration of huperzine A to 
patients with AD [90].  
 
3.4.1.4    Chelidonium majus, Papaveraceae 
Chelidonium majus has traditionally been used as an herbal medicine in the treatment of 
gastric ulcer, gastric cancer, oral infections and general pain in Asian and European 
countries. In a recent study, Cahlikova et al., 2010, demonstrated that the most active of 
the natural occurring alkaloids was chelidonine, which inhibited both human AChE and 
BuChE in a dose-dependent manner with IC50 values of 26.8 ±1.2μM and 31.9 ±1.4μM 
respectively [91].  
 
3.4.2  Terpenoids  
 
3.4.2.1    Salvia lavandulaefolia, Lamiaceae 
The ChE inhibition produced by Salvia lavandulaefolia oil was shown to be partly due to 
the cyclic monoterpenes 1,8-cineole and α-pinene, which were found to inhibit AChE in 
vitro. Upon oral administration of S. lavandulaefolia essential oil to rat‟s, a decreased 
striatal AChE activity in both the striatum and the hippocampus was observed and 
therefore it was postulated that the in vitro and also in vivo inhibition of AChE in select 
brain regions was connected to the activity of either constituents or their metabolites [92]. 
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3.4.2.2    Melissa officinalis, Lamiaceae 
Melissa officinalis has been used for more than 2,000 years owing in part to its reputation 
for restoring memory and promoting long life. Although the constituents have not been 
thoroughly investigated, the plant is known to possess monoterpenes in its essential oil, 
including citral (a mixture of isomers geraniol and nerol), and it is known from previous 
studies that these compounds possess a weak inhibitory effect on AChE [93]. 
 
3.4.2.3    Origanum majorana, Lamiaceae  
Origanum majorana is a plant found in Indian medicine and also more commonly known 
as a spice. In a study testing its inhibitory effect on AChE, the main active component, 
identified as the triterpene ursolic acid, exhibited an IC50 value of 7.5 nM [94].  
 
3.4.3 Withanolides 
 
3.4.3.1    Withania somnifera, Solanaceae 
The root of this plant, also known as Indian ginger, is one of the most highly regarded 
herbs in Ayurvedic medicine where it is classified among the rejuvenating tonics known 
as „Rasayanas‟. Compounds present in W. somnifera are structurally related to steroids 
and more commonly referred to as withanolides. In a study aimed at the cholinesterase 
inhibitory effect of withanolides, Choudhary et al.,2004, isolated and identified six 
compounds, of which four dislayed inhibitory effect against electric eel AChE, while the 
remaining two inhibited horse-serum BuChE [95].   
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4. EXPERIMENTAL PART 
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4.1 General methods 
 
4.1.1  Distillation and evaporation 
Prior to use the solvents were distilled. First, the substances were applied (approx. 5%), 
and then the remaining solvent, about 90% in total, was distilled. Solvents were stored in 
brown glass containers. Evaporation of the chromatograph fractions was carried out on a 
vacuum evaporator under reduced pressure at 40  C. 
 
4.1.2   Chromatography 
 
4.1.2.1   Thin layer chromatography 
Chromatography was carried out in a standard chamber system. Chambers were saturated 
with the mobile phase. The time of saturation was approx. 30 minutes and in the case of 
preparative TLC, approx. 60 minutes. The chromatography was carried out in ascending 
order. 
 
4.1.2.2   Column Chromatography 
Column chromatography was carried out under gradient elution on a silica gel system, 
0.1–0.25mm, deactivated in 10% water. A suspension of the adsorbent in the solvent was 
then poured into the chromatographic column. The prepared column was coated with the 
sample diluted in a small amount of the solvent. The sample was dried in the exsiccator 
and then applied with a small amount of silica gel.  
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4.2 Plant material and equipment 
 
4.2.1  Chemicals and solvents 
Solvents: 
 Cyclohexane   
 Diethylamine   
 Diethylether without stabilizer   
 Ethanol 95%, denatured with methanol (EtOH) 
 Chloroform  (CHCl3)  
 Methanol  (MeOH) 
 Petrol (ČL 2006) 
 Toluene  
 
 Chemicals: 
 Acetic acid 99% p. a.  
 Bismuth subnitrate purum  
 Hydrochloric acid 36% p. a. (HCl) 
 Potassium iodide p. a. (KI) 
 Sodium carbonate anhydrous purum 
 Sodium hydroxide  p. a. (NaOH)  
 Sodium sulfate anhydrous purum  
 Sulfuric acid 96% purum   
 Tartaric acid purum  
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4.2.2  Chemicals and material for analysis of AChE and BuChE (IC50) 
Chemicals:  
 0,1 M phosphate buffer pH 7.4 
 10 mM acetylcholine iodide (Sigma-Aldrich)  
 10 mM butyrylcholine iodide (Sigma-Aldrich)  
 Dimethylsulphoxide p. a. (Sigma-Aldrich)  
 5,5  -Dithiobis(2-nitrobenzoic acid) (DTND) p. a. (Sigma-Aldrich) 
 Eserine (Sigma-Aldrich) 
 Galanthamine hydrobromide (Changsha Organic Herb Inc., China) 
 Huperzin A (Tazhonghui Co., Ltd., China)  
 Sodium dihydrogenphosphate dihydrate p. a. (Lachema)  
 Sodium hydrogen dodecahydrate p. a. (Lachema)  
 
Material: 
 Source of AChE: hemolysed human erythrocytes  
Whole blood was centrifuged for 15 minutes at 10,000 rev / min. The mass obtained 
from red blood cells was washed 3 times with 0.1 M phosphate buffer at pH 7.4 to   
remove residual plasma, 10% (v/v) lysate was prepared in water.  
 Source of BuChE: human plasma  
 Single semi-micro polystyrene cuvette 1.5 ml (PLASTIBRAND) 
 
Equipment: 
 Centrifuge type MPW–340 (Mechanika precyzyjna,Warszaw, Poland)  
 Instrument for measurement of optical rotation: ADP 220 POLARIMETER B+S 
 Micro-heated apparatus Boetius 
 pH meter Φ 72 METER (Beckmann, USA)  
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 UV-Spectrophotometer UVIKON 942 (Kontron Instruments, Switzerland)  
 
4.2.3  Chemicals and material for analysis of antioxidant activity 
 2,2-Diphenyl-1-picrylhydrazyl radical purum (Sigma-Adrich) 
 Quercetin (Sigma-Aldrich) 
 Trolox p.a. (Sigma-Aldrich) 
 
4.2.4  Detection reagents 
 Dragendorf‟s reagent modified according to Munier:  
 Solution A: prepared by dissolving 1.7 g bismuth subnitrate and 20 g tartaric acid in 
80 ml of water. 
 Solution B: prepared by dissolving 16 g potassium iodide in 40 ml water.  
 Stock solution: prepared by mixing solution A and B in ratio of 1:1.Stock solution 
may be stored for some months in a refrigerator (4 °C).  
 Solution for analysis: prepared by adding 5 ml stock solution to 5 ml tartaric acid 
dissolved in 50 ml of water. 
 
4.2.5  Chromatographic plates and adsorbents 
 Aluminum oxide neutral, 100-250 μm (fy Across) 
Commercial chromatographic adsorbent was activated in a layer maximally 2 cm thick at 
200 °C in the dryer for 8 hours. After cooling to ∼ 80 °C, the adsorbent was poured into a 
flask and sealed. After cooling at room temperature, 5% water (w/w) was added and 
equilibrated upon periodic shaking. 
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 Kieselgel 60 GF254, plates for TLC 
For preparation of poured plates (90 x 150 mm), 3.9 g of commercial adsorbent were 
mixed with 13.5 ml water and mixture was homogenized for 30 seconds by using a 
micro-homogenizer. The suspension was poured on the plate, the surface layer was 
planed, and plates were stored in horizontal position for 24 hours at room temperature. 
Solution of fraction was spotted in the form of a line about 10 mm from the upper edge of 
the plate by using an application-tube. 
 
4.3  Description of alkaloid and its isolation 
 
4.3.1  Origin of herbal drug 
Ground tubers of C. yanhusuo were supplied by the company Pragon s.r.o., Prague, and 
verification of the herbal drug was conducted by Assoc. Prof.  L. Opletal.  
 
4.3.2  Preparation of summary extract 
10.8 kg of dry tuber were percolated with 120 liters of 95% ethanol ( 1:11). Collected 
extract was evaporated to a viscous residue, heated at 50 °C, and 2.5 liters of 2% 
hydrochloric acid was added. The brown solution was decanted and the solid residue in 
the flask was homogenized with 1 liter of 2% hydrochloric acid and sonified at 50 °C on 
level 10 (apparatus Sonorex 10HP) for 30 minutes. The suspension was then filtered 
through viscous cellulose and the filtrate was diluted with water to 4.7 liters.  
 
4.3.3  Preparation of extract A from primary extract 
4.7 liters of acidic solution (pH  1) was alkalized by 10% Na2CO3 to pH 9.7 (approx. 7 
liters of solution were obtained). The suspension with alkaloids was operated by ether (5× 
1.6 liters). The organic layer was then desiccated by sodium sulfate, filtered and 
evaporated to dryness. 
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4.3.4  Separation of extract A on particular groups of alkaloids 
Dry residue of extract A was dissolved in 2% hydrochloric acid. This solution was 
filtered and shaken with chloroform. In this manner the mixture of alkaloids was divided 
on chlorides soluble and insoluble in chloroform. Each group of alkaloids was transferred 
into alkaloidal bases, which were dissolved in ether and divided into bases of phenolic 
and non-phenolic origin. Upon completion, four groups of alkaloids from extract A were 
obtained. 
 The mixture of non-phenolic alkaloids, which were obtained from the mixture of 
chlorides soluble in chloroform were examined in this diploma work. The alkaloid 
fraction was obtained from the diploma supervisor (Assoc. Prof. L. Opletal). The first 
part of the separation was performed together with diploma co-worker Buleza Koci. 
 
 
 
 
Fig. 15 TLC of alkaloidal bases from extract A  
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Non-phenolic bases obtained from chlorides soluble in chloroform. Silica gel plates for 
TLC 60F254 (Merck), 50 x 75 mm, toluene + chloroform + diethylamine (70 : 25 : 5), 
developing chamber was saturated by vapor of solvent system, developed 1x, detection 
UV λ = 254 nm, Dragendorf reagent (modified by Munier). 
 
 
4.3.5 Separation of mixture of non-phenolic alkaloids from chlorides soluble in 
chloroform 
9.73 g of yellow-orange oily residue was dissolved in a small volume of chloroform 
(minimal quantity only for dissolution). 30 g of Aluminum oxide neutral was added and 
the mixture was dried. After drying, 5 g of Celite 545 was added and the mixture was 
homogenized. This dry trituration was then applied to the chromatographic column. 
 
Table 1. Column chromatography of non-phenolic bases of alkaloids from 
chlorides soluble in chloroform 
Adsorbent: Aluminium oxide neutral, 100-250 μm, grade 3 activity  
Quantity of adsorbent 350 g 
Layer with extract 3  6 cm 
Layer with adsorbent 3  39 cm 
Dead volume 220 ml 
Time of fraction collection 15-20 minutes 
Fraction volume 100 ml 
 
 
 Each of the fractions was monitored by TLC (Silica gel for TLC 60F254 (Merck), 
plates 50 x 75 mm, solvent system: toluene + chloroform + diethylamine (70 : 25 : 5), 
developing tank was saturated by vapor of solvent system, developed 1×, detected UV λ 
= 254 nm, Dragendorf reagent (modif. according to Munier). 
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 Fractions of the same quality were combined, evaporated under decreased 
pressure and temperature and desiccated in vacuum-desiccator over granulated silica gel. 
 
Table 2. Results of column chromatography of non-phenolic alkaloids from 
chlorides soluble in chloroform  
Fraction  Eluent Weight Description 
1-42 1-12 
13-22 
23-42 
Petrol+CHCl3 95:5 
Petrol+CHCl3 92.5:7.5 
Petrol+CHCl3 90:10 
0.050 g Yellow oil  
43-56 43-56 Petrol+CHCl3 85:15 1.82 g Bright brown, crystals 
57-63 
 
57-59 
60-63 
Petrol+CHCl3 85:15 
Petrol+CHCl3 80:20 
0.57 g Brown-red, crystals 
64-67 64-65 
66-67 
Petrol+CHCl3 80:20 
Petrol+CHCl3 75:25 
0.28 g Brown, crystals 
68-71 68-71 Petrol+CHCl3 75:25 0.86 g Brown, very viscous 
72-75 72-75 Petrol+CHCl3 75:25 0.86 g Dark brown, viscous 
76-97 
 
76-85 
86-95 
96-97 
Petrol+CHCl3 75:25 
Petrol+CHCl3 70:30 
Petrol+CHCl3 25:75 
3.20 g Yellow-brown, crystals 
98-107 98-107 Petrol+CHCl3 25:75 0.19 g Dark brown, very viscous 
108-113 108-113 Petrol+CHCl3 25:75 0.16 g Black, very viscous 
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Fig. 16 Results of column chromatography on aluminum oxide 
Silica gel plates for TLC 60F254 (Merck), 50  75 mm, toluene + chloroform + 
diethylamine 70 : 25 : 5, developing chamber saturated by vapor of solvent system, 
developing 1x, detection UV λ = 254 nm, Dragendorf reagent (modif. according to 
Munier). 
 
 
4.3.6   Isolation of alkaloid from combined fractions 57-63 
 
0.57 g of brown-reddish crystalline mass was dissolved in a 15 ml of mixture chloroform 
+ toluene 95 : 5 (w/w). The solution was filtered through 6.0 g of Aluminum oxide 
neutral in a micro-chromatographic column (diameter × height 8 : 12 mm) and from the 
compound, 20 ml of the mentioned mixture of solvents was eluted. After evaporation of 
filtrate, 0.50 g of yellowish crystalline mass was obtained and designated GC-1.  
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4.4 Method for determining MS spectra 
The spectra were measured on the LC/MS Thermo Finningan LCQDuo, ion trap, 
electrospray ionization in positive mode (ESI+). MS/MS spectra were measured at 
collision energy of 40 eV and the substance was dissolved in methanol. 
 
4.5  Method for determining NMR spectra 
The spectra were measured on a Varian Inova 500 spectrometer with a working 
frequency of 499.9 MHz for 1H and 125.7 MHz for 13C nuclei. 13C NMR spectra were 
measured in 5 mm broadband probe SW, 1 H and all 2D spectra in inverse 5 mm ID PFG 
probe using a modified version of standard pulse sequences. Experiments were measured 
in deuterochloroform at 25 ˚ C.  
Values of chemical shifts are in ppm and are relative to internal standard 
(hexamethyldisilane, 0.04 ppm in 
1
H spectra) or the solvent signal (76.99 ppm in 13C 
spectra)(Dr. M. Kurfürst, Ph.D., Institute of Chemical Process Fundamentals, ASCR, 
Prague). 
 
4.6  Method for determining antioxidant activity- DPPH free-radical scavenging 
assay (EC50) 
Radical scavenging activity of extracts and pure compounds were evaluated by means of 
the DPPH (2,2´-diphenyl-1-picrylhydrazyl radical) test using an SIA (PC-controlled 
Sequential Injection Analysis system) method developed in our laboratory [96].  The 
stock solution of extract/pure compound was prepared by dissolving 4 mg of the 
extract/pure compound in 4 ml of aqueous 50% w/w ethanol during 10 minutes of 
sonication; the same solvent was used for appropriate dilution of the extract/pure 
compound stock solution (1, 0.5, 0.25, 0.01 mg/mL). DPPH solution (0.1 mM) was 
prepared by dissolving 3.9 mg DPPH in 100 mL 50 % w/w ethanol. The automated 
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method was based on the known reaction of stable DPPH with antioxidants resulting in 
bleaching of DPPH due to its “quenching” by interaction with the analytes. The decrease 
in the absorbance of DPPH measured at 525 nm was related to the concentration of 
antioxidant in the tested solution. The percentage of inhibition of DPPH was estimated by 
using the formula: % QDPPH = (1-Ax/A0) x 100, where A0 was the height of the peak of the 
blank sample and Ax was the height of the peak after the extract/pure compound was 
added. All measurements were made in triplicate. The DPPH radical scavenging activity 
of samples was expressed as EC50 (mg/mL for extracts, µM for pure compounds), which 
was the amount of sample necessary to decrease by 50% the light absorbance. 
 
4.7 Methods for determinating inhibitory activity against AChE and BuChE 
 
4.7.1 Preparation of red blood cells ghost for AChE and BuChE 
Ghosts were prepared from freshly drawn blood (taken from healthy volunteers), to 
which 1 mL of sodium citrate per 10 mL of blood was added, according to a slightly 
modified method of Steck and Kant [97]. Briefly plasma (HuBuChE) was removed from 
the whole blood by centrifugation at 4000 rpm in a Boeco U-32R centrifuge with a 
Hettich 1611 rotor. Red blood cells were transferred to 50 mL tubes and washed 3 times 
with 5 mM phosphate buffer (pH 7.4) containing 150 mM sodium chloride (12000 rpm, 
Avanti J-30I, rotor JA-30.50). The washed erythrocytes were stirred with 5 mM 
phosphate buffer (pH 7.4) for 10 min to ensure lysis. The lysed cells were centrifuged at 
20,000 rpm for 10 minutes and then the ghosts (HuAChE) were washed 3 times with 
phosphate buffer. 
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4.7.2  AChE and BuChE assay (IC50) 
HuAChE and HuBuChE activities were determined with a modified method of Ellman et 
al.,[98] at concentrations 500, 250, 125, 50, 25, 12.5, 5, 2.5, 0.5, and 0.25 μg/mL using 
acetylthiocholine iodide (ATChI) and butyrylthiocholine iodide (BTChI) as substrates, 
respectively. Briefly, 25-50 μL of ghosts or plasma, 650 μL of DTNB and 25 μL of either 
the sample or appropriate solvent, as a blank sample, were added to the semi-micro 
cuvette. The reaction was initiated by addition of substrate (ATChI or BTChI). The final 
proportion of DTNB to substrate was 1 : 1. The increase of absorbance at 436 nm (∆A) 
was measured for one minute using a Shimadzu UV-1611 spectrophotometer. Each 
measurement was repeated three times. Galanthamine and huperzine A were used as 
positive controls. The IC50 and EC50 values were calculated with the use of GraphPad 
Prism 5.02 software. The inhibition (in %) was calculated according to the formula: %I = 
100-(∆ABL/∆ASA)*100, where ∆ABL= increase of absorbance of a blank sample and 
∆ASA= increase of absorbance of the measured sample.  
 
4.8 Method for determining optical rotation 
The optical rotation was measured on polarimeter ADP 220 BS ethanol. 
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5. RESULTS 
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5.1 Structural analysis of compound GC-1 
The structure of the isolated compound was determined by comparing spectral data with 
those reported in the literature as (+)-corydaline (CAS: 3907-48-0). 
 
5.1.1 MS analysis of (+)-corydaline 
 
ESI-MS m/z [M+H]
+
 370.24 (100). 
 
 
 
Fig.17 MS Spectrum of (+)-corydaline 
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5.1.2   MS/MS analysis of (+)-corydaline 
 
MS/MS m/z  355.16 (20; [M-CH3]
+
), 338.14 (15), 308.11 (12), 218.14 (22), 192.14 (100; 
[C11H14O2N]
+
), 165.07 (25; [C10H13O2]
+
). 
 
 
                        
Fig. 18 MS/MS spectrum of (+)-corydaline 
 
 
 
 
 
 
 
 
 
 50 
 
 
Fig.19 MS/MS spectrum of corydaline and its proposed retro-Diels-Alder (RDA) pathway 
 
 
5.1.3  NMR analysis of (+)-corydaline  
 
 
 
 
 
 
Fig. 20 Structure of isolated compound (+)-corydaline 
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5.1.3.1   
1
H-NMR analysis of (+)-corydaline 
 
1
H NMR (CDCl3, 25°C):  
0.95 (3H, d, J = 7.0 Hz, R-CH3); 2.59 - 3.17 (4H, m, H-5, H-6); 3.20 (1H, dd, J = 7.0 Hz, 
H-13); 3.50 (1H, d, J = 15.9 Hz, H-8α), 3.68 (1H, br s, H-13a), 3.85 (6H, s, 2 R-OCH3), 
3.87 (6H, s, 2 R-OCH3), 4.20 (1H, d, J =15.9 Hz, H-8ß), 6.60 (1H, s, H-4), 6.68 (1H, s, 
H-1), 6.82 (1H, d, J = 8.4 Hz Hz, H-11), 6.90 (1H, d, J = 8.4 Hz, H-12) 
 
 
Fig.21
 1
H-NMR spectrum of (+)-corydaline 
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5.1.3.2   
13
C-NMR analysis of (+)-corydaline 
 
13
C NMR (CDCl3, 25°C): 
29.23, C-5; 36.45, C-13; 51.72, C-6; 54.18, C-8; 56.09, C-3a; 56.12, C-10a; 56.32, C-2a; 
59.54, C-14; 60.42, C-9a; 108.83, C-1; 111.26, C-11; 111.60, C-4; 124.08, C-12; 126.93, 
C-4a; 127.88, C-12a; 128.75, C-8a; 129.75, C-14a; 145.34, C-9; 147.71, C-2; 147.80, C-
3; 150.54, C-1 
 
Fig. 22 
13
C NMR spectrum of (+)-corydaline 
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5.1.3.3   Optical rotation 
[α]D
23
 + 312 ° (EtOH; c = 0.2) 
 
 
5.2  Inhibitory activity of (+)- corydaline against AChE and BuChE 
 
Table 3   In vitro HuAChE and HuBuChE inhibitory activity of isolated compound 
Compound IC50 (μM)
a 
AChE BuChE 
(+)-Corydaline 40.5 ± 1.9 >1000 
Galanthamin
b 6.9 ± 0.3 156 ± 6.9 
Huperzin
b 0.25 ± 0.01 >1000 
 
 
a 
Results are the mean of free replications; 
b 
Reference compounds 
 
 
 
5.3  Antioxidant activity of (+)-corydaline  
 
Table 4    Antioxidant activity of isolated compound 
Compound EC50 (μM)
a 
(+)-Corydaline >1000 
Quercetin
 b 25.3 ± 1.2 
Trolox
 b 27.8± 0.8 
 
 
a 
Results are the mean of free replications; 
b 
Reference compounds 
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6. DISCUSSION 
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On the department of pharmaceutical botany and ecology, Faculty of Pharmacy in Hradec 
Králové, of Charles University, focus has been aimed at testing the biological activity of 
various alkaloids, notably isoquinoline type, with regard to their inhibitory activity on 
ChEs. This particular interest stemmed from the ever growing knowledge supporting the 
theory that these natural compounds could be employed as potential structural prototypes 
in the future development of more active ChE inhibitors. This class of agents is renowned 
for their use as the treatment of choice in mild-to-moderate symptomatic therapy of AD. 
  The aim of this work was to isolate alkaloids from the crude extract A of C. 
yanhusuo (from the part of chlorides non-phenolic alkaloids soluble in chloroform) by 
column chromatography and preparative thin-layer chromatography, and testing the 
biological activities related to ChE inhibition and antioxidant effect.  
 After chromatographic separation and fractionation of the extract A, one pure 
alkaloid was isolated. The alkaloid was termed GC-1 and further identified as (+)-
corydaline on the basis of MS and NMR spectral studies. (+)-Corydaline is a tertiary 
alkaloid belonging to the structural group of isoquinoline alkaloids and can be further 
classified as having a tetrahydroberberine skeletal backbone (see Fig. 20). 
 The isolated alkaloid (+)-corydaline was further investigated on its inhibitory 
effect against human erythrocytic AChE and BuChE using the spectrophotometric 
method devised by Ellman [98], as well as antioxidant activity by use of the DPPH test. 
(+)-Corydaline was found to inhibit AChE in a dose-dependent manner with an IC50 value 
of 40.5 ± 1.9 μM, with huperzine A and galanthamine as positive controls. However, (+)-
corydaline was found inactive against BuChE due to its IC50 value >1000 μM. The 
antioxidant activity was also considered negligible due to a value of EC50. >1000 μM.   
 Corydaline was isolated from C. yanhusuo in previous investigations [6, 9, 15, 96-
98]. In a study by Hung et al., 2008, corydaline was found to weakly inhibit AChE with 
an IC50 value of 30.7 ± 1.5 μM when mouse brain cortex was used as the source of 
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enzyme [9]. Interestingly, in another study on corydaline isolated from Corydalis cava, it 
was found to be the most active compound, inhibiting electric eel AChE in a dose- 
dependent manner with an IC50 value of 15 ± 3 μM [101]. Moreover, in the same study 
by Adsersen et al., 2007, corydaline was also found inactive against BuChE due to IC50 > 
100 μM [101]. When comparing the spectrum of results obtained in this work with that of 
previous studies, it is important to note that differences in IC50 values could be due, at 
least in part, to the choice in enzyme origin. 
 In addition to possessing inhibitory activity against AChE, previous studies have 
demonstrated other unique pharmacological properties of corydaline. In one such study, 
corydaline was found to inhibit the enzyme GABA-transaminase, thus dispaling the basic 
mechanism of drug action used in the treatment of convulsive disorders [102]. Further 
more, corydaline derived from C. yanhusuo was found to exhibit significant 
antinociceptive effects with particularly high concentrations in the striatum [10]. 
 The potential use of isoquinoline alkaloids against neurodegenerative processes in 
the human brain are concerned not only with their activity against AChE and BuChE, but 
another working theory in this area is on the inhibition of β- secretase (BACE1), as well 
as inhibition of NMDA receptors. From these reasons, it was also necessary to isolate 56 
alkaloids that have previously been reported in literature for activity against human ChEs. 
 Based on the results obtained from this work along with comparisons from previous 
studies mentioned above, it can be said that (+)-corydaline does not prove sufficiently 
effective in the inhibition of AChE due to its weak IC50 values, and therefore may not be 
used as a direct means of alternative therapy in AD. However, the knowledge obtained 
with regard to the biological activity of (+)-corydaline can be considered as an important 
base in future production of more active synthetic analogues, where novel therapeutic 
strategies for dementia treatment may benefit from the combination of conventional 
Western approach and traditional Oriental medical. 
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β-A  - β-amyloid 
AChE  - acetylcholinesterase 
AD  - Alzheimer‟s disease 
APP  - amyloid precursor protein 
BACE1 - β-secretase 
BuChE - butyrylcholinesterase 
ChE  - cholinesterase 
CNS  - central nervous system 
COX-2 - cyclooxygenase 2 
D1/D2  - dopamine 1/ dopamine 2 receptor 
DA  - dopamine 
DPPH  - 2,2´-diphenyl-1-picrylhydrazyl 
EC50  - effective concentration  
GABAA - gamma amino butyric acid A subtype 
HuAChE -human acetylcholinesterase 
HuBuChE -human butyrylcholinesterase 
IC50  -inhibitory concentration 
IL-6/ IL-8  - interleukin 
iNOS  - inducible nitric oxide synthase 
MAPK - mitogen activated protein kinase 
NMDA - N-methyl-D-aspartate (receptor) 
NFT(s) - neurofibrillary tangle(s) 
PGE2  - prostaglandin E2 
PS1, PS2 - presenilin 1, presenilin 2 
THP   - tetrahydropalmatine 
TNF-α  - tumor necrosis factor-α 
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Abstrakt 
Univerzita Karlova v Praze  
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Katedra farmaceutické botaniky a ekologie  
Kandidát:  Gabriella Cipra 
Konzultant:  Doc. RNDr. Lubomir Opletal, CSc. 
Název diplomové práce:  Biologická aktivita obsahových látek rostlin XVII. Alkaloidy 
Corydalis yanhusuo W.T.Wang.  
 
V rámci studia rostlin s obsahem alkaloid , které inhibují aktivitu lidské erytrocytární 
acetylcholinesterasy a sérové butyrylcholinesterasy byl studován taxon Corydalis 
yanhusuo.  
K izolaci bylo pou ito 10.8 kg suchých hlíz. Primární extrakt byl připraven 
perkolací 95% EtOH. V této diplomové práci byl zpracován výtřepek A-Et2O (pH 9,7). 
Alkaloidy tohoto výtřepku byly rozděleny na baze, jejich  chloridy jsou rozpustné a 
nerozpustné v chloroformu. Z ka dé uvedené frakce byly dále získány alkaloidy 
fenolické a nefenolické. Práce spo ívala v dělení alkaloid  výtřepku s obsahem 
nefenolických alkaloid , jejich  chloridy jsou rozpustné v CHCl3. Z této směsi byl 
pomocí sloupcové chromatografie na Al2O3, preparativní TLC izolován (+)-korydalin. 
Látka byla  identifikována na základě hmotnostního spektra, NMR spekter, optické 
otá ivosti a srovnáním údaj  s literárními daty. Při sledování vlivu (+)-korydalinu na 
lidskou AChE a BuChE a následném matematickém výpo tu byla pro (+)-korydalin 
zjištěno: IC50 40,5 ± 1,9 μM. Antioxida ní aktivita (DPPH test) vykázala hodnotu EC50 > 
1000 μM. 
Klíčová slova: acetylcholinesterasa, butyrylcholinesterasa, alkaloidy, Alzheimerova 
choroba, Corydalis yanhusuo 
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Candidate: Gabriella Cipra 
Consultant: Assoc. Prof. RNDr. Lubomir Opletal, CSc. 
Title of Thesis: Biological activity of plant metabolites  XVII. Alkaloids of Corydalis 
yanhusuo W.T. Wang  
 
In the process of screening for plants containing alkaloids potentially inhibiting human 
erythrocytic AChE and human BuChE, Corydalis yanhusuo was studied.  
 10.8 kg of dried tuber was percolated with 120 liters of 95% ethanol. From the 
primary extract, extracts with individual types of alkaloids were prepared. 
  In this diploma thesis only one extract was processed (extract type A-ether, pH 
9.7).  Alkaloids from this extract were separated into bases which chlorides were either 
soluble or insoluble in chloroform. From each of the above mentioned fractions phenolic 
and non-phenolic alkaloids were obtained. Alkaloids were separated from extract of non-
phenolic chlorides soluble in chloroform. From this mixture (+)-corydaline (labeled GC-
1) was isolated by the use of column chromatography on alumina and preparative TLC on 
silica gel. This compound was preliminary identified according to data of MS spectra, 
NMR spectra, and optical rotation and by comparison with literature data. The biological 
activity of (+)-corydaline on human AChE and BuChE was found to be: IC50 40.5 ± 1.9 
μM and IC50 >1000 μM, respectively, and antioxidative activity (DPPH test) was EC50 
>1000 μM. 
Key words: acetylcholinesterase, butyrylcholinesterase, alkaloids, Alzheimer‟s disease, 
Corydalis yanhusuo. 
